Introducing way more signals! We've added more signal sources to capture the full customer journey.

Learn More!
Ridgeback Biotherapeutics

Ridgeback Biotherapeutics

Headquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. Ridgeback markets EbangaTM for the treatment of Ebola and has a late-stage development pipeline which includes molnupiravir for the treatment of COVID-19. Development of molnupiravir is entirely funded by Ridgeback Biotherapeutics and Merck & Co., Inc. All equity capital in Ridgeback Biotherapeutics, LP originated from Wayne and Wendy Holman, who are committed to investing in and supporting medical technologies that will save lives. The team at Ridgeback is dedicated to working toward finding life-saving and life-changing solutions for patients and diseases that need champions.

Last updated on

About Ridgeback Biotherapeutics

Founded

2006

Estimated Revenue

$1M-$10M

Employees

1-10

Category

Industry

Investment Banking

Location

City

New York City

State

New York

Country

United States
Ridgeback Biotherapeutics

Ridgeback Biotherapeutics

Find your buyer within Ridgeback Biotherapeutics

Tech Stack (27)

search

Programming Languages And Frameworks

Collaboration

IT Security

Payment

Content Management System

Email Hosting Providers

Web Hosting Providers

Syndication Techniques